A Rare Complication Following Transarterial Chemoembolization for Hepatocellular Carcinoma  by Lin, Wei-Chen et al.
Case Report 
A Rare Complication Following Transarterial Chemoembolization for 
Hepatocellular Carcinoma 
Wei-Chen Lin, Tsang-En Wang*, Horng-Yang Wang, Shou-Chuan Shih 
Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan 
Abstract. 
According to the Taiwanese government’s official annual report listing the top 10 causes of 
death, cancer was the leading cause of death in Taiwan in 2013, with hepatocellular carcinoma 
ranking second among those cancer deaths. Transarterial chemoembolization has been shown to 
be widely used in the treatment for unresectable disease, and increase survival in patients with 
intermediate stage hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer 
classification. Despite relatively low morbidity, however, major complications may be seen. We 
report the case of a 54-year-old male with hepatocellular carcinoma who suffered from severe 
abdominal pain after transarterial chemoembolization, where further studies found a rare com-
plication of subcapsular hematoma of the right kidney. 
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病例報告  
肝動脈化療栓塞治療肝癌的罕見併發症 
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中文摘要 
  根據 2013 年台灣年度十大死因報告，癌症仍然佔首位，其中肝癌是第二常見的癌症
死因。肝動脈化療栓塞已廣泛用於治療不能手術切除的肝癌和提升巴塞隆納肝癌分類為
中期患者的存活率。儘管肝動脈化療栓塞併發症不高，嚴重的併發症仍會發生。我們報
告一位 54 歲肝癌患者在做完肝動脈化療栓塞後有嚴重腹痛，之後檢查發現右腎包膜下血
腫之罕見併發症。 
 
關鍵字: 肝動脈化療栓塞治療、肝細胞癌、併發症 
 
INTRODUCTION 
Cancer was the leading cause of death in Taiwan 
in 2013, according to the official annual report issued 
by the Taiwan Department of Health. In particular, 
hepatocellular carcinoma (HCC) was the second lead-
ing cause among those cancer deaths [1]. Compared 
with the frequently limited options for other cancers, 
treatment selection for HCC is variable, such as sur-
gery, percutaneous ethanol injection, radiofrequency 
ablation, and transarterial chemoembolization (TACE). 
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Such options exist in part because patient prognosis 
depends not only on the tumor extent but also hepatic 
function reserve [2,3]. TACE is now widely used for 
the treatment of HCC in Taiwan. Major complications 
in the technique of TACE occur in 5% of patients, 
with a 1% risk of death [4]. Various complications 
associated with TACE for HCC include hepatic failure, 
hepatic infarction, liver abscess, bilomas, cholecystitis, 
gastrointestinal mucosal lesions, and multiple intra-
hepatic aneurysms [5]. 
The most common vascular complication related 
to arterial access is hepatic artery injury [4]. Here, we 
report the case of a 54-year-old male with hepatocel-
lular carcinoma who suffered from severe right ab-
dominal pain after TACE. Additional investigation 
revealed a rare complication of subcapsular hematoma 
of the right kidney.  
 
CASE REPORT 
A 54-year-old male with a past history of chronic 
hepatitis B and hepatocellular carcinoma was diag-
nosed 3 years ago after S6 partial hepatectomy. He 
didn’t receive antiviral treatment for chronic hepatitis 
B (HBe Ag: negative, HBV DNA: 525   IU/mL). A 3.5 
cm target-like mass in S7 was found by abdominal 
ultrasonography prior to admission during regular 
follow-up.  Dynamic abdominal computed tomogra-
phy (CT) showed a 4.1 cm hypervascular mass with 
washout of contrast enhancement. With a presumptive 
diagnosis of recurrent hepatocellular carcinoma, the 
patient received TACE by superselective catheteriza-
tion of the feeding artery from the right hepatic artery 
and therapeutic chemo-embolization with 40 mg Dox-
orubicin mixed with 10 ml Lipiodol, 1.0 gm Cefazolin,  
 
 
 
 
 
 
 
 
 
 
Figure 1. Ultrasonography. A heterogenous echogenic 
mass was found in the right kidney, 9.1x6.5 
cm in size 
 
 
and gelfoam piece as embolizers. 
After TACE, the patient suffered from severe right 
flank pain and right upper quadrant pain. His hemo-
dynamic status was stable. Laboratory data revealed 
deteriorate liver function, including GOT/GPT level 
(44/33 to 142/142 IU/L; normal range: 15-41/14-40 
IU/L), and total/direct bilirubin level (2.6/0.6 to 
4.5/0.8 mg/dL). The patient's hemoglobin level de-
creased rapidly (9.9 to 5.9 g/dL) in 2 days and pre-
sented with acute kidney injury (creatinine levels: 0.6 
to 1.6 mg/dL). Follow-up ultrasonography showed a 
huge heterogenous mass in the right kidney (Figure 1). 
When the patient was administered a whole abdominal 
CT scan without contrast, retention of contrast medi-
um in the right kidney and hyperdense lesion in the 
right subcapsular and perirenal space was noted, 
compatible with internal bleeding (Figure 2A). There 
was a large area of lipiodol collection in the liver pre-
senting HCC post TAE (Figure 2B). 
The patient was treated conservatively with blood 
transfusion and intravenous volume replacement. A 
protruding soft mass lesion in the right flank then ec-
chymosis over right flank was noted on day 7 post 
TACE. The hematoma had decreased when a fol-
low-up ultrasonography was obtained 10 days after 
the procedure. He was discharged uneventfully on day  
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Figure 2. Abdominal CT scan without contrast en-
hancement. (A) Retention of contrast me-
dium was found in the right kidney (arrow). 
There was evidence of subcapsular and pe-
ri-renal area hematoma (H). (B) A large 
area of lipiodol was collected in S7 seg-
ment of liver presenting lipiodol TACE for 
management of HCC 
 
 
 
12. Follow-up with abdominal CT revealed resolution 
large subcapsular hematoma of the right kidney 1 
month later (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Abdominal CT scan without contrast en-
hancement. Resolution of subcapsular he-
matoma (H) in the right kidney was found 
1 month later 
 
 
DISCUSSION 
Transarterial chemoembolization is the most 
widely performed treatment for patients with HCC 
who are not eligible for curative surgery or ablation. 
The survival benefit and efficacy of TACE has been 
also confirmed by numerous randomized controlled 
trials and meta-analysis [6-8]. The procedure involves 
gaining percutaneous transarterial access to the hepat-
ic artery with an arterial sheath, usually by puncturing 
the common femoral artery in the right groin and 
passing a catheter guided by a wire via the abdominal 
aorta, through the celiac trunk and common hepatic 
artery, and finally into the proper branch of the hepatic 
artery which supplies the tumor. 
However, a variety of complications related to the 
chemoembolic agents and to manipulation guide wire 
may occur during or after TACE. These complications 
can be classified into two major categories: vascular 
and nonvascular cause. 
Vascular complications of TACE include puncture 
site complications, injury to the hepatic artery itself 
and non-target embolization. Other complications, 
such as arterial rupture and acute thrombosis, are more 
serious and may result in blood loss or otherwise 
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threaten the patient's life. Non-vascular complications 
of TACE include post TACE syndrome (occurs in 
around 90% of patients) [4], infection, biliary stricture, 
GI bleeding, hepatic failure and renal failure.  
The most common vascular complication related 
to arterial access is hepatic artery injury [4], which 
leads to hepatic artery spasm and inflammatory con-
striction, and severe cases may even lead to occlusion, 
dissection, intrahepatic and extrahepatic collateraliza-
tion, and aneurysm formation in the hepatic artery [9]. 
The incidence of significant hepatic artery damage 
was 16% per artery and 48% per patient [9]. 
When a catheter is being advanced against re-
sistance, the celiac artery or gastroduodenal artery 
may cause iatrogenic dissection and guide wire-induced 
perforation. The renal artery injury complications are 
mostly from renal artery angioplasty or stent dilatation 
procedures [10]. The incidence of serious iatrogenic 
injuries of the renal artery after percutaneous revascu-
larization procedures is not rare, having been calcu-
lated by researchers in early series to occur in 
6.5-22.8% of patients undergoing angioplasty [11,12]. 
Many of these complications may be recognized im-
mediately, but presentations of some complications 
can be delayed [13]. 
We noted that the guide wire tip was in the right 
renal artery before it got into the hepatic artery in this 
patient. This guidewire tip may have been in a wrong 
position and therefore caused perforation of an in-
trarenal branch artery. This injury was not recognized 
during the procedure and caused retention of contrast 
in the right kidney during contrast injection. Owing to 
no obvious hemodynamic change, we did not perform 
a second angiogram on this patient. However, if any 
sign of persistent hemorrhage or hemodynamic insta-
bility had been evident, a second angiogram and a 
possible transcatheter embolization procedure should 
be performed immediately. 
In most cases of traumatic renal artery rupture or 
pseudoaneurysm, they are usually mild and can be 
cured spontaneously with conservative treatment [14]. 
However, surgical intervention is often necessary in 
patients whose perirenal hemorrhage extends progres-
sively, and whose hemodynamics remain unstable de-
spite aggressive anti-shock treatment [15]. With ad-
vances in intervention technology in recent years, 
percutaneous renal artery embolization has become an 
alternative to surgery for the treatment of uncontrolled 
iatrogenic arterial kidney injuries because the proce-
dure is minimally invasive, with a shorter duration of 
hospitalization required. Furthermore, it is safe and 
associated with high technical and clinical success 
rates and not associated with a significant worsening 
of renal function [16]. 
 
CONCLUSIONS 
Transarterial chemoembolization has been widely 
used to treat patients with hepatocellular carcinoma. 
As with any other interventional procedure, there is a 
small risk of hemorrhage and/or damage to blood 
vessels. To avoid arterial perforation, physicians 
should be careful to wedge the guide wire during se-
lective catheterization and be familiar with the proce-
dure’s potential side effects. Thereafter, post-surgical 
follow-up on any noted clinical symptoms should be 
timely, where ultrasonographic testing can be im-
portant to best evaluate any complication of TACE. 
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